<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220809055652N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-09-22</date_registration>
      <primary_sponsor>Kashan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of inositol on fertility in Frozen embryo transfer cycles in Poly cystic ovary syndrome</public_title>
      <acronym></acronym>
      <scientific_title>The effect of inositol on fertility in Frozen embryo transfer cycles in Poly cystic ovary syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-10-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65214</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: It will be done by simple random method and using lottery. Each patient will receive a number or code. We will write the numbers on pieces of paper. Then we will put the pieces of paper in a container and select the samples for the intervention and control groups according to the sample size from the numbers obtained from the lottery, Blinding description: According to coordination with the pharmacy of Shahid Beheshti Hospital in Kashan, the considered drugs are provided to the patients in two packages A and B. Patients in the control group will receive package A, which includes their routine medications, plus folic acid, which is produced with a similar appearance by a reputable pharmaceutical company, and patients in the intervention group will receive package B, which includes their routine medications plus inofolic.</study_design>
      <phase>3</phase>
      <hc_freetext>Polycystic ovarian syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Control group: According to coordination with the pharmacy of Shahid Beheshti Hospital in Kashan, the drugs considered in this study are provided to the patients in two packages A and B. Patients in the control group received Package A, which included their own routine medications plus folic acid manufactured in a similar form by a reputable pharmaceutical company. These patients take folic acid for 8 weeks before the embryo transfer date, and then the embryo transfer is done with a suitable quality and the biochemical pregnancy rate (slight and temporary increase in B-hCG level), Clinical Pregnancy rate (observation of the fetus with activity heart in 6-7 weeks of pregnancy) and the rate of spontaneous abortion (pregnancy loss in 5-12 weeks of pregnancy) will be investigated in this group. Intervention 2: Intervention group: According to coordination with Shahid Beheshti Kashan hospital pharmacy, the drugs considered in this study are provided to the patients in two packages A and B. Patients in the intervention group will receive package B, which includes their routine medications along with inofolic. The patients of the intervention group received these drugs for eight weeks and then the embryo transfer was done with good quality and the amount of biochemical pregnancy (slight and temporary increase in B-hCG level), the amount of clinical pregnancy (observation of the fetus with cardiac activity in 6 weeks) 7-pregnancy) and the rate of spontaneous abortion (pregnancy loss in 5-12 weeks of pregnancy) will be investigated in this group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is "No more information"</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zohreh Talebi Mazreshahi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Beheshti Hospital, Qotb-e Ravandi Blvd, Kashan, Isfahan province, Iran. Post code:8715988111</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8715988111</zip>
        <telephone>+98 31 5558 9258</telephone>
        <email>talebi-z@kaums.ac.ir</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zohreh Talebi Mazreshahi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Beheshti Hospital, Qotb-e Ravandi Blvd, Kashan, Isfahan province, Iran. Post code:8715988111</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8715988111</zip>
        <telephone>+98 31 5558 9258</telephone>
        <email>talebi-z@kaums.ac.ir</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>People with polycystic ovary syndrome based on sonographic and laboratory findings.
Ages between 20 and 40 years old
Candidate to enter the FET procedure at Infertility Center of Shahid Beheshti Hospital, Kashan, based on infertility records.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>People with uterine abnormalities (such as Asherman's syndrome, fibroids, polyps and adenomyosis diagnosis)
Inositol contraindications
Treatment cycles with embryo donation or prenatal genetic screening,
The mother is over 40 years old
Endometriosis
Unexplained Infertility</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Control group: According to coordination with the pharmacy of Shahid Beheshti Hospital in Kashan, the drugs considered in this study are provided to the patients in two packages A and B. Patients in the control group received Package A, which included their own routine medications plus folic acid manufactured in a similar form by a reputable pharmaceutical company. These patients take folic acid for 8 weeks before the embryo transfer date, and then the embryo transfer is done with a suitable quality and the biochemical pregnancy rate (slight and temporary increase in B-hCG level), Clinical Pregnancy rate (observation of the fetus with activity heart in 6-7 weeks of pregnancy) and the rate of spontaneous abortion (pregnancy loss in 5-12 weeks of pregnancy) will be investigated in this group.</i_keyword>
      <i_keyword>Intervention group: According to coordination with Shahid Beheshti Kashan hospital pharmacy, the drugs considered in this study are provided to the patients in two packages A and B. Patients in the intervention group will receive package B, which includes their routine medications along with inofolic. The patients of the intervention group received these drugs for eight weeks and then the embryo transfer was done with good quality and the amount of biochemical pregnancy (slight and temporary increase in B-hCG level), the amount of clinical pregnancy (observation of the fetus with cardiac activity in 6 weeks) 7-pregnancy) and the rate of spontaneous abortion (pregnancy loss in 5-12 weeks of pregnancy) will be investigated in this group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fertility rate. Timepoint: Two months. Method of measurement: Clinical examination of pregnancy with the criterion of fetal heart observation in ultrasound.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kashan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-07-26</approval_date>
        <contact_name>Ethics Committee in Research  of Faculty of Medicine, Kashan University of Medical Sciences</contact_name>
        <contact_address>Faculty of Medicine, Kashan University of Medical Sciences, Qotb-e Ravandi Blvd, Kashan, Isfahan province, Iran. Post code:8715988111 Kashan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
